UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): July 25, 2018

 

E-QURE CORP.
(Exact Name of Registrant as Specified in its Charter)

 

Commission File No.: 000-54862

 

Delaware   47-1691054
(State of Incorporation)   (I.R.S. Employer Identification No.)
     
20 West 64th Street, Suite 39G, New York, NY   10023
(Address of Principal Executive Offices)   (ZIP Code)

 

Registrant’s Telephone Number, including area code: (972) 8-916-7333

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective July 25, 2018, E-Qure Corp. (the “Registrant”) announced the appointment of Mr. Ohad Goren, its Chief Executive Officer since June 2014, and Mr. Itsik Ben-Yesha, its Chief Technology Officer since June 2014, as members of the Registrant’s Board of Directors, joining Mr. Ron Weissberg and Dr. Michael Sessler on the Registrant’s Board.

 

Ohad Goren, age 49, Chief Executive Officer and Director. During the past five years, Mr. Goren has served in the following positions: from 2011 through 2013 Mr. Goren served as an advisor to several biotech and high-tech startup companies. During 2010 and 2011, Mr. Goren served as CEO of Pollogen Ltd., a private Israeli company engaged in the development, manufacture and marketing of medical aesthetic devices with sales in Europe, North and South America, and major Asian countries. Prior to joining Pollogen Ltd., during 2008 to 2009, Mr. Goren served as a consultant to startup companies principally in the biotechnology and hi-tech industries. From 2005 through 2008, Mr. Goren was the CEO of Lifewave Ltd., a public Israeli company, where he had responsibility for Lifewave’s IPO, overseeing the development of its chronic wound treatment device and Lifewave’s regulatory compliance, among other duties, and participated in the purchase by the Registrant of Lifewave’s patent for its chronic wound treatment device. From 1997 to 2005 Mr. Goren served as the Marketing and Sales Manager of the Services Division of Oracle Corp., in Israel. From 1990 to 1997 Mr. Goren served as the Deputy Consul at the Israeli Embassy, Washington, D.C. Mr. Goren received his BA degree from the University of Maryland, in the U.S.

 

Itsik Ben Yesha, age 67, Chief Technology Officer and Director: Mr. Ben-Yesha has served as the Registrant’s CTO since June 2014. From 1991 through 2013, Mr. Ben Yesha was the founder and a partner of Hisense Ltd., an Israeli medical device company for respiratory monitoring devices for infants. He previously served as Executive Vice President of Lifewave Ltd. From 1998 to 2003 Mr. Ben Yesha was the Executive Vice President and VPL Division President with Valor Computerized Systems Ltd., a CAD/CAM Software company listed on the Frankfurt Stock Exchange and later acquired by Mentor Graphics (NASDAQ: MENT). From 1979 to 1997, Mr. Ben Yesha served in Tadiran Telecom Group in various rolls, starting as a R&D engineer, designing computerized electronic exchanges (Tadex, Coral), and finally serving as the CFO of Tadiran Wireless Telecom division, bringing it from $0 to $50 million in annual sales within 3 years.

 

There are no family relationships between Messrs. Goren and Ben-Yesha and any of the Registrant’s other officers and directors. Other than as described in the 2017 Annual Report on Form 10-K filed with the SEC on April 17, 2018, there are no transactions to which the Registrant or any of its subsidiaries is a party in which Messrs. Goren and Ben-Yesha have had a material interest subject to disclosure under Item 404(a) of Regulation S-K.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  E-QURE CORP.
     
  By: /s/: Ron Weissberg
  Name: Ron Weissberg
  Title: Chairman

 

Date: July 30, 2018